Shionogi agreed to acquire IntraBio, a Texas-based rare-disease company, for $2 billion upfront, adding a marketed treatment covering two inherited conditions to its expanding rare disease portfolio. The move also extends Shionogi’s emphasis on oral small molecules and real-world commercial assets as it builds out its downstream pipeline.